Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Tissue Regenix Group (TRX)

Price 59.00p on 26-12-2024 at 05:12:31
Change 0.00p 0%
Buy 60.00p
Sell 58.00p
Buy / Sell TRX Shares
Last Trade: -
Day's Volume: 0
Last Close: 59.00p
Open: 0.00p
ISIN: GB00BNTXR104
Day's Range 0.00p - 0.00p
52wk Range: 50.00p - 74.00p
Market Capitalisation: £42m
VWAP: 0.00p
Shares in Issue: 71m

Recent Trades History Tissue Regenix Group (TRX)

Buy/Sell Volume Trade Prc Trade Type Trade Time

Share Price History for Tissue Regenix Group

Time period:
to
Date Open High Low Close Volume

Share News for Tissue Regenix Group

IN BRIEF: Tissue Regenix contacts firms as it considers possible sale

4th Nov 2024 18:21

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - In response to press reports, say that it is conducting a review of strategic options, which may include soliciting offers for Tissue Regenix. Accordingly, the firm has contacted a limited number of potential counterparties to assess whether they could put forward a proposal "that would deliver greater value to Tissue Regenix's shareholders than pursuing a standalone independent strategy". Says it has not received any indicative non-binding proposals to date, and says there can be no certainty any offer will be made. Read More

EARNINGS AND TRADING: Blackbird loss narrows; Futura Medical in profit

10th Sep 2024 21:21

(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Tuesday and not separately reported by Alliance News: Read More

UK earnings, trading statements calendar - next 7 days

3rd Sep 2024 11:31

Read More

IN BRIEF: Tissue Regenix eyes revenue and adjusted profit growth

16th Jul 2024 11:30

Tissue Regenix Group PLC - Leeds, England-based regenerative medical devices company - Says trading in the first half of 2024 was strong, as it expects revenue to have climbed 16% to USD16.4 million from USD14.1 million a year prior. "The BioRinse segment continued to deliver solid growth driven by increased efficiencies, while the commercial reorganisation of the dCELL segment continued to show benefits, demonstrating robust growth within the period," Tissue Regenix says. It will report its full half-year results on September 10. Read More

Tissue Regenix purchases Texas facility to generate cost savings

14th Jun 2024 14:36

(Alliance News) - Tissue Regenix Group PLC on Friday said it purchased an existing facility as part of phase 1 and 2 expansion plans. Read More

FTSE 100 Latest
Value8,136.99
Change0.00

Login to your account

Forgot Password?

Not Registered